Home » Posts tagged with » UCB
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]

Amgen, UCB resubmit BLA of EVENITY osteoporosis drug to FDA

Amgen and UCB have resubmitted the biologics license application (BLA) of their investigational osteoporosis drug EVENITY (romosozumab) to the US Food and Drug Administration (FDA) for treatment of osteoporosis in postmenopausal women at high risk for fracture. A bone-forming monoclonal antibody, EVENITY is said to increase bone formation and simultaneously decrease bone resorption, in order […]

Continue reading …